Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Champions Biotechnology signs agreement to test Cephalon's CEP-32496 in Biomerk Tumorgraft platform

Champions Biotechnology, Inc., an oncology drug development company with a predictive preclinical platform aimed at accelerating the development and enhancing the value of oncology drugs, announced the establishment of an agreement with Cephalon, Inc., a global biopharmaceutical company, for the testing of the Cephalon novel B-Raf inhibitor CEP-32496 in Champions' Biomerk Tumorgraft™ platform.

8 Sep 2010

Tikcro reports $3.2 million net loss for second-quarter 2010

Tikcro Technologies Ltd. today reported results for the second quarter and six months ended June 30, 2010.

7 Sep 2010

Genetic predisposition reduces breast, ovarian cancer risk with preventive surgeries: Study

A long-term study of women with a genetic predisposition for breast or ovarian cancer showed that those who elected major preventive surgeries had a significantly reduced risk of those cancers.

4 Sep 2010

ImmunoCellular Therapeutics updates accomplishments in Letter to Shareholders

As the summer comes to a close, I wanted to update you on the Company's accomplishments this year, which set the stage for an exciting fall. The first eight months of the year have been very successful, with the Company attaining many of its goals, despite a very difficult economic environment, which has created challenges for many small biotechnology companies. Today, IMUC is in its best financial position ever and well positioned to validate the success it achieved in a Phase I trial for ICT-107, its dendritic cell-based cancer vaccine product candidate.

3 Sep 2010

Preventive surgery protects against breast, ovarian cancer in women carrying BRCA1, BRCA2 gene mutations

Women who have gene mutations that put them at high risk of ovarian and breast cancer can significantly reduce the risk of developing or dying from these cancers by having their healthy ovaries or breasts removed, according to a new study reported in the Sept. 1 issue of the Journal of the American Medical Association.

3 Sep 2010

GOG to conduct Phase II trial on primary peritoneal cancer

Oncolytics Biotech Inc. announced today that the Gynecologic Oncology Group (GOG) intends to conduct a randomized Phase II trial of weekly paclitaxel versus weekly paclitaxel with REOLYSIN(R) in patients with persistent or recurrent, ovarian, fallopian tube or primary peritoneal cancer (GOG186H).

3 Sep 2010

Study: Preemptive surgery may help prevent cancer for some women

A study published in the Journal of the American Medical Association suggests that women with a gene mutation linked to breast and ovarian cancer face lower risks of developing such cancer after receiving mastectomies or having their ovaries removed, The Wall Street Journal reports.

2 Sep 2010

Genetic testing, preventive surgeries can save women from ovarian and breast cancers

Women should be aware that options for these preventive surgeries have improved, the authors note. A laparoscopic salpingo-oophorectomy is a relatively low-risk procedure and can be done in an out-patient setting. And cosmetic options for women getting mastectomies have greatly improved.

2 Sep 2010

Salpingo-oophorectomy and mastectomy decrease risk of cancer in women with BRCA1/2 gene mutations

Women at increased risk of breast and ovarian cancer because of inherited mutations of the BRCA1 or BRCA2 genes who had prophylactic mastectomy or salpingo-oophorectomy (removal of the fallopian tubes and ovaries) had an associated decreased risk of breast cancer and ovarian cancer, according to a study in the September 1 issue of JAMA.

2 Sep 2010

Eight signs of cancer: Study

Scientists have now identified eight signs of cancer that need immediate attention. These can predict the risk of cancer with such accuracy in certain age groups that patients should be referred to a specialist straight away unless there is a good explanation that is is something else.

30 Aug 2010

Access Pharmaceuticals to highlight Cobalamin nanotechnology at ACS National Meeting

ACCESS PHARMACEUTICALS, INC.,a biopharmaceutical company specializing in products for cancer and supportive care, announced that its Director of Chemistry and Quality, Dr. Ric Zarzycki will give an invited presentation today on the Company's Cobalamin nanoparticle technology at a thought-leadership symposium being held at the American Chemical Society's ("ACS") 240th National Meeting & Exposition, at Boston Convention and Exhibition Center in Boston, Massachusetts, August 22-26, 2010.

25 Aug 2010

Arrayit selects PMA pathway for OvaDx Pre-Symptomatic Ovarian Cancer Screening Test

Arrayit Corporation, a leader in life sciences and healthcare technology, announces today that the company has chosen the Premarket Approval pathway for its OvaDx Pre-Symptomatic Ovarian Cancer Screening Test. While the standard for a PMA is higher than for a 510(k), the company believes that a PMA OvaDx submission can achieve a Class III PMA approval, the most stringent approval level granted by the FDA for in vitro diagnostic devices.

23 Aug 2010

Researchers find new way to study oncogene's role in DNA repair

A key step in understanding the origins of familial breast cancer has been made by two teams of scientists at the University of California, Davis. The researchers have purified, for the first time, the protein produced by the breast cancer susceptibility gene BRCA2 and used it to study the oncogene's role in DNA repair.

23 Aug 2010

FDA grants orphan drug designation to ImmunoGen's lorvotuzumab mertansine for small-cell lung cancer

ImmunoGen, Inc., a biotechnology company that develops antibody-based targeted anticancer products, today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation to its lorvotuzumab mertansine (formerly IMGN901) product candidate when used for the treatment of small-cell lung cancer (SCLC).

19 Aug 2010

ImmunoCellular Therapeutics raises $6.5 million in second quarter 2010

ImmunoCellular Therapeutics today announced second quarter results for the period ended June 30, 2010. The Company utilized $1.13 million of cash in its operations during the quarter. The increase in net burn is reflective of increased personnel costs as well as increase in Research and Development costs associated with the planned phase II clinical trial for ICT-107.

18 Aug 2010

Cancer Institute of New Jersey expands 'Quality and Outcomes in Cancer Care Research Program'

Looking to gain further understanding about the impact of cancer on patients and families, The Cancer Institute of New Jersey (CINJ) is expanding its Quality and Outcomes in Cancer Care (QOCC) Research Program by welcoming nationally-recognized population science researcher Sharon Manne, PhD. Dr. Manne, who is the recipient of major grant awards from the National Institutes of Health (NIH) for her work in behavioral science, was most recently at the Fox Chase Cancer Center in Philadelphia. CINJ is a Center of Excellence of UMDNJ-Robert Wood Johnson Medical School.

17 Aug 2010

Nanoparticle-based gene silencing system inhibits angiogenesis process in tumor growth

A protein associated with cancer progression when abundant inside of tumors also unexpectedly regulates the creation of new blood vessels that feed the tumor outside, a research team led by scientists at The University of Texas MD Anderson Cancer Center reports in the August edition of Cancer Cell.

17 Aug 2010

Experimental drug benefits women with advanced ovarian or breast tumours caused by BRCA gene faults

An experimental drug called olaparib has been shown to shrink tumours in women whose advanced cancers were caused by faults in their BRCA genes.

17 Aug 2010

SIK2 impacts cell division cycle, regulates ovarian cancer response to chemotherapy: Research

For the first time, Salt Inducible Kinase 2 (SIK2) has been found to play a critical role in cell division and to regulate the response of some ovarian cancers to chemotherapy.Findings were reported by researchers from The University of Texas MD Anderson Cancer Center in the August issue of Cancer Cell. The study adds to growing evidence that combination therapies targeting different phases of the cell division cycle are vital for optimal cancer treatment.

17 Aug 2010

EntreMed second quarter 2010 net loss increases to $0.62 per share

EntreMed, Inc.,a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, today reported financial results for the three and six-month periods ending June 30, 2010.

16 Aug 2010

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Champions Biotechnology signs agreement to test Cephalon's CEP-32496 in Biomerk Tumorgraft platform

Tikcro reports $3.2 million net loss for second-quarter 2010

Genetic predisposition reduces breast, ovarian cancer risk with preventive surgeries: Study

ImmunoCellular Therapeutics updates accomplishments in Letter to Shareholders

Preventive surgery protects against breast, ovarian cancer in women carrying BRCA1, BRCA2 gene mutations

GOG to conduct Phase II trial on primary peritoneal cancer

Study: Preemptive surgery may help prevent cancer for some women

Genetic testing, preventive surgeries can save women from ovarian and breast cancers

Salpingo-oophorectomy and mastectomy decrease risk of cancer in women with BRCA1/2 gene mutations

Eight signs of cancer: Study

Access Pharmaceuticals to highlight Cobalamin nanotechnology at ACS National Meeting

Arrayit selects PMA pathway for OvaDx Pre-Symptomatic Ovarian Cancer Screening Test

Researchers find new way to study oncogene's role in DNA repair

FDA grants orphan drug designation to ImmunoGen's lorvotuzumab mertansine for small-cell lung cancer

ImmunoCellular Therapeutics raises $6.5 million in second quarter 2010

Cancer Institute of New Jersey expands 'Quality and Outcomes in Cancer Care Research Program'

Nanoparticle-based gene silencing system inhibits angiogenesis process in tumor growth

Experimental drug benefits women with advanced ovarian or breast tumours caused by BRCA gene faults

SIK2 impacts cell division cycle, regulates ovarian cancer response to chemotherapy: Research

EntreMed second quarter 2010 net loss increases to $0.62 per share

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in